These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27545758)

  • 21. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
    Sáez-Lara MJ; Robles-Sanchez C; Ruiz-Ojeda FJ; Plaza-Diaz J; Gil A
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.
    Ni Y; Zhuge F; Nagashimada M; Ota T
    Nutrients; 2016 Jun; 8(7):. PubMed ID: 27347998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
    Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
    Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease.
    Tejada S; Capó X; Mascaró CM; Monserrat-Mesquida M; Quetglas-Llabrés MM; Pons A; Tur JA; Sureda A
    Curr Pharm Des; 2021; 27(22):2558-2570. PubMed ID: 32303170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
    J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).
    Mager DR; Iñiguez IR; Gilmour S; Yap J
    JPEN J Parenter Enteral Nutr; 2015 Jan; 39(1):73-84. PubMed ID: 23976771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications.
    Karimi M; Abiri B; Guest PC; Vafa M
    Methods Mol Biol; 2022; 2343():19-35. PubMed ID: 34473313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease.
    Liu Q; Zhu L; Cheng C; Hu YY; Feng Q
    Curr Pharm Des; 2017; 23(34):5136-5162. PubMed ID: 28925892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fucoidan ameliorates steatohepatitis and insulin resistance by suppressing oxidative stress and inflammatory cytokines in experimental non-alcoholic fatty liver disease.
    Heeba GH; Morsy MA
    Environ Toxicol Pharmacol; 2015 Nov; 40(3):907-14. PubMed ID: 26498267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids.
    Wang K; Tan W; Liu X; Deng L; Huang L; Wang X; Gao X
    Biomed Pharmacother; 2021 May; 137():111326. PubMed ID: 33556870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
    Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
    J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.
    Qureshi K; Abrams GA
    Clin Obes; 2016 Apr; 6(2):117-23. PubMed ID: 26856683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women.
    Bruno Ade S; Rodrigues MH; Alvares MC; Nahas-Neto J; Nahas EA
    Climacteric; 2014 Aug; 17(4):465-71. PubMed ID: 24517420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
    Koukias N; Buzzetti E; Tsochatzis EA
    Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
    Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
    Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population.
    Sathiaraj E; Chutke M; Reddy MY; Pratap N; Rao PN; Reddy DN; Raghunath M
    Eur J Clin Nutr; 2011 Apr; 65(4):533-7. PubMed ID: 21346716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.